Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	oxidoreductase activity, acting on the aldehyde or oxo group of donors, disulfide as acceptor	PDHA1 PDHA2 BCKDHA	6.58e-06	9	87	3	GO:0016624
GeneOntologyMolecularFunction	JUN kinase activity	MAPK8 MAPK9	5.61e-05	3	87	2	GO:0004705
GeneOntologyMolecularFunction	pyruvate dehydrogenase (acetyl-transferring) activity	PDHA1 PDHA2	5.61e-05	3	87	2	GO:0004739
GeneOntologyMolecularFunction	pyruvate dehydrogenase (NAD+) activity	PDHA1 PDHA2	2.78e-04	6	87	2	GO:0034604
GeneOntologyMolecularFunction	pyruvate dehydrogenase [NAD(P)+] activity	PDHA1 PDHA2	2.78e-04	6	87	2	GO:0034603
GeneOntologyMolecularFunction	pyruvate dehydrogenase activity	PDHA1 PDHA2	2.78e-04	6	87	2	GO:0004738
GeneOntologyMolecularFunction	enzyme regulator activity	CCNF RALGAPA1 RALGDS PPP2R2A FRY BNIP2 TBC1D4 ASAP3 CCAR2 SERPINC1 MAPK8 MAPK9 CABIN1 DOCK6 SPATA13	1.12e-03	1418	87	15	GO:0030234
GeneOntologyMolecularFunction	oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor	PDHA1 PDHA2 BCKDHA	1.20e-03	48	87	3	GO:0016620
GeneOntologyCellularComponent	alpha-ketoacid dehydrogenase complex	PDHA1 PDHA2 BCKDHA	5.81e-05	18	89	3	GO:0045240
GeneOntologyCellularComponent	oxidoreductase complex	NDUFC2-KCTD14 ACACB PDHA1 PDHA2 BCKDHA NDUFC2	6.52e-05	161	89	6	GO:1990204
GeneOntologyCellularComponent	super elongation complex	AFF2 AFF3	2.66e-04	6	89	2	GO:0032783
GeneOntologyCellularComponent	pyruvate dehydrogenase complex	PDHA1 PDHA2	4.94e-04	8	89	2	GO:0045254
GeneOntologyCellularComponent	inner dynein arm	DNHD1 DNAH12	7.89e-04	10	89	2	GO:0036156
MousePheno	abnormal thyroid gland morphology	ZMYND11 BRD2 RB1 CCDC80 MARVELD2 MEN1	4.27e-06	87	69	6	MP:0000681
MousePheno	increased thyroid tumor incidence	RB1 CCDC80 MEN1	1.85e-05	11	69	3	MP:0010316
MousePheno	increased pituitary adenoma incidence	DRD2 RB1 MEN1	4.03e-05	14	69	3	MP:0002041
MousePheno	increased pituitary gland tumor incidence	DRD2 RB1 MEN1	5.02e-05	15	69	3	MP:0010320
Domain	E1_dh	PDHA1 PDHA2 BCKDHA	2.00e-06	6	88	3	PF00676
Domain	DH_E1	PDHA1 PDHA2 BCKDHA	2.00e-06	6	88	3	IPR001017
Domain	NDUF_C2	NDUFC2-KCTD14 NDUFC2	2.19e-05	2	88	2	PF06374
Domain	NADH-UbQ_OxRdtase_b14.5b_su	NDUFC2-KCTD14 NDUFC2	2.19e-05	2	88	2	IPR009423
Domain	Pyrv_DH_E1_asu_subgrp-y	PDHA1 PDHA2	2.19e-05	2	88	2	IPR017597
Domain	THDP-binding	PDHA1 PDHA2 BCKDHA	2.79e-05	13	88	3	IPR029061
Domain	-	PDHA1 PDHA2 BCKDHA	2.79e-05	13	88	3	3.40.50.970
Domain	Elf-1_N	ELF1 ELF2	6.56e-05	3	88	2	PF12310
Domain	TF_Elf_N	ELF1 ELF2	6.56e-05	3	88	2	IPR022084
Domain	TF_AF4/FMR2	AFF2 AFF3	1.31e-04	4	88	2	IPR007797
Domain	REJ	PKD1L1 PKDREJ	1.31e-04	4	88	2	PS51111
Domain	REJ_dom	PKD1L1 PKDREJ	1.31e-04	4	88	2	IPR014010
Domain	AF-4	AFF2 AFF3	1.31e-04	4	88	2	PF05110
Domain	MAPK_JNK	MAPK8 MAPK9	2.17e-04	5	88	2	IPR008351
Domain	PKD/REJ-like	PKD1L1 PKDREJ	3.25e-04	6	88	2	IPR002859
Domain	REJ	PKD1L1 PKDREJ	3.25e-04	6	88	2	PF02010
Domain	PKD_channel	PKD1L1 PKDREJ	1.17e-03	11	88	2	PF08016
Domain	PKD1_2_channel	PKD1L1 PKDREJ	1.17e-03	11	88	2	IPR013122
Domain	MAP_kinase_CS	MAPK8 MAPK9	1.40e-03	12	88	2	IPR003527
Domain	MAPK	MAPK8 MAPK9	1.40e-03	12	88	2	PS01351
Domain	Dynein_heavy_dom-2	DNHD1 DNAH12	1.93e-03	14	88	2	IPR013602
Domain	DHC_N2	DNHD1 DNAH12	1.93e-03	14	88	2	PF08393
Domain	DHC_fam	DNHD1 DNAH12	2.21e-03	15	88	2	IPR026983
Domain	Dynein_heavy_dom	DNHD1 DNAH12	2.21e-03	15	88	2	IPR004273
Domain	Dynein_heavy	DNHD1 DNAH12	2.21e-03	15	88	2	PF03028
Domain	LH2	PKD1L1 PKDREJ	3.20e-03	18	88	2	SM00308
Domain	PLAT	PKD1L1 PKDREJ	4.35e-03	21	88	2	PS50095
Domain	-	PKD1L1 PKDREJ	4.35e-03	21	88	2	2.60.60.20
Domain	PLAT	PKD1L1 PKDREJ	4.35e-03	21	88	2	PF01477
Domain	PLAT/LH2_dom	PKD1L1 PKDREJ	4.35e-03	21	88	2	IPR001024
Pathway	REACTOME_INITIATION_OF_NUCLEAR_ENVELOPE_NE_REFORMATION	PPP2R2A VRK1 VRK2	6.65e-05	17	67	3	MM14920
Pathway	REACTOME_INITIATION_OF_NUCLEAR_ENVELOPE_NE_REFORMATION	PPP2R2A VRK1 VRK2	9.42e-05	19	67	3	M29617
Pathway	WP_HEREDITARY_LEIOMYOMATOSIS_AND_RENAL_CELL_CARCINOMA_PATHWAY	ACACB PDHA1 PDHA2	1.10e-04	20	67	3	M39751
Pathway	KEGG_MEDICUS_PATHOGEN_HIV_VPR_TAT_TO_TNF_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	2.20e-04	5	67	2	M47570
Pathway	KEGG_MEDICUS_ENV_FACTOR_PARAQUAT_TO_FAS_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	2.20e-04	5	67	2	M49021
Pathway	KEGG_MEDICUS_PATHOGEN_HTLV_1_TAX_TO_TNF_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	2.20e-04	5	67	2	M49005
Pathway	PID_RB_1PATHWAY	BRD2 RB1 ELF1 MAPK9	2.54e-04	65	67	4	M279
Pathway	WP_NANOPARTICLEMEDIATED_ACTIVATION_OF_RECEPTOR_SIGNALING	TLN1 MAPK8 MAPK9	3.09e-04	28	67	3	M39572
Pathway	REACTOME_RUNX1_REGULATES_TRANSCRIPTION_OF_GENES_INVOLVED_IN_BCR_SIGNALING	ELF1 ELF2	3.30e-04	6	67	2	M27798
Pathway	REACTOME_PDH_COMPLEX_SYNTHESIZES_ACETYL_COA_FROM_PYR	PDHA1 PDHA2	3.30e-04	6	67	2	M48273
Pathway	REACTOME_PDH_COMPLEX_SYNTHESIZES_ACETYL_COA_FROM_PYR	PDHA1 PDHA2	3.30e-04	6	67	2	MM17245
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_HTT_TO_TNF_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	3.30e-04	6	67	2	M47680
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_ABETA_TO_IRE1A_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	3.30e-04	6	67	2	M47698
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_INACTIVATED_DJ1_TO_FAS_JNK_SIGNALING_PATWHAY	MAPK8 MAPK9	3.30e-04	6	67	2	M47712
Pathway	KEGG_PANCREATIC_CANCER	RALGDS RB1 MAPK8 MAPK9	3.38e-04	70	67	4	M9726
Pathway	WP_CHROMOSOMAL_AND_MICROSATELLITE_INSTABILITY_IN_COLORECTAL_CANCER	RALGDS EXOC2 MAPK8 MAPK9	3.96e-04	73	67	4	M39758
Pathway	WP_ACETYLCHOLINE_SYNTHESIS	PDHA1 PDHA2	4.60e-04	7	67	2	MM15975
Pathway	WP_ACETYLCHOLINE_SYNTHESIS	PDHA1 PDHA2	4.60e-04	7	67	2	M39640
Pathway	KEGG_MEDICUS_REFERENCE_IRE1A_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	4.60e-04	7	67	2	M47697
Pathway	KEGG_MEDICUS_REFERENCE_FAS_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	4.60e-04	7	67	2	M47711
Pathway	WP_13Q1212_COPY_NUMBER_VARIATION	MAPK8 MAPK9 SPATA13	5.53e-04	34	67	3	M48103
Pathway	KEGG_MEDICUS_ENV_FACTOR_METALS_TO_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	6.12e-04	8	67	2	M47814
Pathway	BIOCARTA_FBW7_PATHWAY	CUL1 RB1	7.84e-04	9	67	2	MM1568
Pathway	BIOCARTA_FBW7_PATHWAY	CUL1 RB1	7.84e-04	9	67	2	M22053
Pathway	WP_THIAMINE_METABOLIC_PATHWAYS	PDHA1 BCKDHA	7.84e-04	9	67	2	M39774
Pathway	WP_PANCREATIC_ADENOCARCINOMA_PATHWAY	RALGDS RB1 MAPK8 MAPK9	8.40e-04	89	67	4	M39732
Pathway	KEGG_PYRUVATE_METABOLISM	ACACB PDHA1 PDHA2	8.94e-04	40	67	3	M7934
Pathway	BIOCARTA_SKP2E2F_PATHWAY	CUL1 RB1	9.77e-04	10	67	2	MM1384
Pathway	REACTOME_ACTIVATION_OF_THE_AP_1_FAMILY_OF_TRANSCRIPTION_FACTORS	MAPK8 MAPK9	9.77e-04	10	67	2	MM15135
Pathway	BIOCARTA_SKP2E2F_PATHWAY	CUL1 RB1	9.77e-04	10	67	2	M6031
Pathway	REACTOME_ACTIVATION_OF_THE_AP_1_FAMILY_OF_TRANSCRIPTION_FACTORS	MAPK8 MAPK9	9.77e-04	10	67	2	M13962
Pathway	REACTOME_SIGNALING_BY_ALK_IN_CANCER	CUL1 RB1 MAPK8 MAPK9	9.90e-04	93	67	4	M42521
Pathway	REACTOME_RHO_GTPASE_CYCLE	RALGAPA1 VRK2 DST TEX2 MTMR1 DOCK6 COPS2 SPATA13	1.08e-03	439	67	8	MM15595
Pathway	REACTOME_CYCLIN_D_ASSOCIATED_EVENTS_IN_G1	CUL1 PPP2R2A RB1	1.18e-03	44	67	3	MM15377
Pathway	KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_BIOSYNTHESIS	PDHA1 PDHA2	1.19e-03	11	67	2	M17946
Pathway	REACTOME_RHO_GTPASE_CYCLE	RALGAPA1 VRK2 DST TEX2 MTMR1 DOCK6 COPS2 SPATA13	1.27e-03	450	67	8	M27078
Pathway	BIOCARTA_P27_PATHWAY	CUL1 RB1	1.42e-03	12	67	2	MM1472
Pathway	KEGG_MEDICUS_REFERENCE_MLK_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	1.42e-03	12	67	2	M47929
Pathway	REACTOME_CYCLIN_D_ASSOCIATED_EVENTS_IN_G1	CUL1 PPP2R2A RB1	1.43e-03	47	67	3	M29724
Pathway	PID_ERBB1_DOWNSTREAM_PATHWAY	RALGDS PPP2R2A MAPK8 MAPK9	1.55e-03	105	67	4	M164
Pathway	PID_ANGIOPOIETIN_RECEPTOR_PATHWAY	ELF1 ELF2 MAPK8	1.62e-03	49	67	3	M92
Pathway	BIOCARTA_P27_PATHWAY	CUL1 RB1	1.68e-03	13	67	2	M17977
Pathway	KEGG_MEDICUS_REFERENCE_EGF_EGFR_RAS_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	1.68e-03	13	67	2	M47594
Pathway	WP_GLYCOLYSIS_AND_GLUCONEOGENESIS	PDHA1 PDHA2 FBP2	1.82e-03	51	67	3	MM15928
Pathway	KEGG_MEDICUS_REFERENCE_P27_CELL_CYCLE_G1_S	CUL1 RB1	1.95e-03	14	67	2	M47427
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: III. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	RALGAPA1 RALGDS PPP2R2A NRXN3 DST TEX2 NAT10 SPIRE1 INO80 DOCK6 HERC4	1.14e-07	529	89	11	14621295
Pubmed	Retinoblastoma protein interacts with ATF2 and JNK/p38 in stimulating the transforming growth factor-beta2 promoter.	RB1 MAPK8 MAPK9	3.22e-07	6	89	3	11566021
Pubmed	Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators.	RALGAPA1 PPP2R2A VRK2 TBC1D4 BRD2 SUB1 NAT10 MTMR1 CCAR2 BCKDHA MARVELD2 MAPK8 MAPK9 GOLGA4	4.41e-07	1049	89	14	27880917
Pubmed	The in vivo Interaction Landscape of Histones H3.1 and H3.3.	VRK1 ZMYND11 BRD2 RB1 SUB1 NAT10 ELF1 ELF2 INO80 CABIN1 MEN1	4.54e-07	608	89	11	36089195
Pubmed	JNK1/2-dependent phosphorylation of angulin-1/LSR is required for the exclusive localization of angulin-1/LSR and tricellulin at tricellular contacts in EpH4 epithelial sheet.	MARVELD2 MAPK8 MAPK9	8.99e-07	8	89	3	24889144
Pubmed	Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes.	CUL1 VRK1 IFRD1 LIN37 TBC1D4 RB1 MTMR1 CCAR2 SIM2 MAPK9 CABIN1 MEN1	1.94e-06	857	89	12	25609649
Pubmed	Human transcription factor protein interaction networks.	PRR12 PPP2R2A LIN37 DST SLF1 BRD2 ACACB RB1 NAT10 ELF1 CCAR2 ELF2 INO80 CABIN1 ZNF471	3.27e-06	1429	89	15	35140242
Pubmed	JNK-dependent Stat3 phosphorylation contributes to Akt activation in response to arsenic exposure.	MAPK8 MAPK9	6.48e-06	2	89	2	22696236
Pubmed	C-Jun N-terminal kinase (JNK) isoforms play differing roles in otitis media.	MAPK8 MAPK9	6.48e-06	2	89	2	25311344
Pubmed	The DREAM complex through its subunit Lin37 cooperates with Rb to initiate quiescence.	LIN37 RB1	6.48e-06	2	89	2	28920576
Pubmed	Genetic inhibition or activation of JNK1/2 protects the myocardium from ischemia-reperfusion-induced cell death in vivo.	MAPK8 MAPK9	6.48e-06	2	89	2	16043490
Pubmed	Combined Activities of JNK1 and JNK2 in Hepatocytes Protect Against Toxic Liver Injury.	MAPK8 MAPK9	6.48e-06	2	89	2	26708719
Pubmed	Ablation of the spindle assembly checkpoint by a compound targeting Mps1.	MAPK8 MAPK9	6.48e-06	2	89	2	16113653
Pubmed	c-Jun N-terminal kinase 1 is deleterious to the function and survival of murine pancreatic islets.	MAPK8 MAPK9	6.48e-06	2	89	2	18853132
Pubmed	DREAM and RB cooperate to induce gene repression and cell-cycle arrest in response to p53 activation.	LIN37 RB1	6.48e-06	2	89	2	31400114
Pubmed	Ultrafine particles from diesel engines induce vascular oxidative stress via JNK activation.	MAPK8 MAPK9	6.48e-06	2	89	2	19154785
Pubmed	Role of the MAPK/cJun NH2-terminal kinase signaling pathway in starvation-induced autophagy.	MAPK8 MAPK9	6.48e-06	2	89	2	29950132
Pubmed	Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance.	MAPK8 MAPK9	6.48e-06	2	89	2	16818881
Pubmed	Lack of augmentation of tumor spectrum or severity in dual heterozygous Men1 and Rb1 knockout mice.	RB1 MEN1	6.48e-06	2	89	2	17173065
Pubmed	Specific role of JNK in the maintenance of the tumor-initiating capacity of A549 human non-small cell lung cancer cells.	MAPK8 MAPK9	6.48e-06	2	89	2	23912840
Pubmed	Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: a retrospective observational cohort study.	VRK1 VRK2	6.48e-06	2	89	2	27456229
Pubmed	Suppression of inflammatory cytokine production by carbon monoxide involves the JNK pathway and AP-1.	MAPK8 MAPK9	6.48e-06	2	89	2	12857751
Pubmed	JNK1, but not JNK2, is required in two mechanistically distinct models of inflammatory arthritis.	MAPK8 MAPK9	6.48e-06	2	89	2	21839715
Pubmed	Structural characterization of human Vaccinia-Related Kinases (VRK) bound to small-molecule inhibitors identifies different P-loop conformations.	VRK1 VRK2	6.48e-06	2	89	2	28790404
Pubmed	JNK is required for maintaining the tumor-initiating cell-like properties of acquired chemoresistant human cancer cells.	MAPK8 MAPK9	6.48e-06	2	89	2	26235742
Pubmed	Prevention of steatosis by hepatic JNK1.	MAPK8 MAPK9	6.48e-06	2	89	2	19945406
Pubmed	C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma.	MAPK8 MAPK9	6.48e-06	2	89	2	12538493
Pubmed	Hypothermia attenuates ischemia/reperfusion-induced endothelial cell apoptosis via alterations in apoptotic pathways and JNK signaling.	MAPK8 MAPK9	6.48e-06	2	89	2	19596001
Pubmed	Inhibition of Jun NH2-terminal kinases suppresses the growth of experimental head and neck squamous cell carcinoma.	MAPK8 MAPK9	6.48e-06	2	89	2	17908987
Pubmed	c-Jun N-terminal kinase 1/2 activation by tumor necrosis factor-alpha induces insulin resistance in human visceral but not subcutaneous adipocytes: reversal by liver X receptor agonists.	MAPK8 MAPK9	6.48e-06	2	89	2	19567513
Pubmed	Increased JNK in males compared with females in a rodent model of abdominal aortic aneurysm.	MAPK8 MAPK9	6.48e-06	2	89	2	22316675
Pubmed	Defective antiviral CD8 T-cell response and viral clearance in the absence of c-Jun N-terminal kinases.	MAPK8 MAPK9	6.48e-06	2	89	2	24673683
Pubmed	c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis.	MAPK8 MAPK9	6.48e-06	2	89	2	11435459
Pubmed	[Sodium butyrate do not induce the program of premature senescence in transformants with JNK1,2 knockout].	MAPK8 MAPK9	6.48e-06	2	89	2	19140343
Pubmed	Modulation of the response of prostate cancer cell lines to cisplatin treatment using small interfering RNA.	MAPK8 MAPK9	6.48e-06	2	89	2	23900581
Pubmed	Inhibition of c-Jun N-terminal kinase attenuates low shear stress-induced atherogenesis in apolipoprotein E-deficient mice.	MAPK8 MAPK9	6.48e-06	2	89	2	21629969
Pubmed	c-Jun N-terminal protein kinase 1 (JNK1), but not JNK2, is essential for tumor necrosis factor alpha-induced c-Jun kinase activation and apoptosis.	MAPK8 MAPK9	6.48e-06	2	89	2	15572687
Pubmed	Hepatotoxicity mediated by pyrazole (cytochrome P450 2E1) plus tumor necrosis factor alpha treatment occurs in c-Jun N-terminal kinase 2-/- but not in c-Jun N-terminal kinase 1-/- mice.	MAPK8 MAPK9	6.48e-06	2	89	2	21748763
Pubmed	Purinergic (ATP) signaling stimulates JNK1 but not JNK2 MAPK in osteoblast-like cells: contribution of intracellular Ca2+ release, stress activated and L-voltage-dependent calcium influx, PKC and Src kinases.	MAPK8 MAPK9	6.48e-06	2	89	2	18625195
Pubmed	The JNKs differentially regulate RNA polymerase III transcription by coordinately modulating the expression of all TFIIIB subunits.	MAPK8 MAPK9	6.48e-06	2	89	2	19620725
Pubmed	Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway.	MAPK8 MAPK9	6.48e-06	2	89	2	16571730
Pubmed	JNK inhibition reduces apoptosis and neovascularization in a murine model of age-related macular degeneration.	MAPK8 MAPK9	6.48e-06	2	89	2	23341606
Pubmed	c-Jun N-terminal kinase 2 promotes enterocyte survival and goblet cell differentiation in the inflamed intestine.	MAPK8 MAPK9	6.48e-06	2	89	2	28098247
Pubmed	c-Jun N-terminal kinase is upregulated in patients with hypospadias.	MAPK8 MAPK9	6.48e-06	2	89	2	23273084
Pubmed	An initial phase of JNK activation inhibits cell death early in the endoplasmic reticulum stress response.	MAPK8 MAPK9	6.48e-06	2	89	2	27122189
Pubmed	JNK2 up-regulates hypoxia-inducible factors and contributes to hypoxia-induced erythropoiesis and pulmonary hypertension.	MAPK8 MAPK9	6.48e-06	2	89	2	29118187
Pubmed	Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2.	MAPK8 MAPK9	6.48e-06	2	89	2	10559486
Pubmed	Polymorphisms in MEN1 and DRD2 genes are associated with the occurrence and characteristics of pituitary adenomas.	DRD2 MEN1	6.48e-06	2	89	2	27185868
Pubmed	c-Jun N-terminal kinase activity is required for efficient respiratory syncytial virus production.	MAPK8 MAPK9	6.48e-06	2	89	2	28062184
Pubmed	JNK regulates muscle remodeling via myostatin/SMAD inhibition.	MAPK8 MAPK9	6.48e-06	2	89	2	30072727
Pubmed	c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8(+) T cell activation.	MAPK8 MAPK9	6.48e-06	2	89	2	11927626
Pubmed	c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 signaling pathways have divergent roles in CD8(+) T cell-mediated antiviral immunity.	MAPK8 MAPK9	6.48e-06	2	89	2	11927625
Pubmed	Efficient keratinocyte differentiation strictly depends on JNK-induced soluble factors in fibroblasts.	MAPK8 MAPK9	6.48e-06	2	89	2	24335928
Pubmed	Identification of two novel human putative serine/threonine kinases, VRK1 and VRK2, with structural similarity to vaccinia virus B1R kinase.	VRK1 VRK2	6.48e-06	2	89	2	9344656
Pubmed	Inhibition of cell proliferation and cell cycle progression by specific inhibition of basal JNK activity: evidence that mitotic Bcl-2 phosphorylation is JNK-independent.	MAPK8 MAPK9	6.48e-06	2	89	2	14704147
Pubmed	Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells.	MAPK8 MAPK9	6.48e-06	2	89	2	14724588
Pubmed	The mouse Laf4 gene: exon/intron organization, cDNA sequence, alternative splicing, and expression during central nervous system development.	AFF2 AFF3	6.48e-06	2	89	2	12079280
Pubmed	Coordination of JNK1 and JNK2 is critical for GADD45alpha induction and its mediated cell apoptosis in arsenite responses.	MAPK8 MAPK9	6.48e-06	2	89	2	16973625
Pubmed	Differential roles of JNK in ConA/GalN and ConA-induced liver injury in mice.	MAPK8 MAPK9	6.48e-06	2	89	2	18772342
Pubmed	The expression pattern of the pyruvate dehydrogenase E1 alpha subunit genes during spermatogenesis in adult mouse.	PDHA1 PDHA2	6.48e-06	2	89	2	1735460
Pubmed	c-Jun NH2-terminal kinase-2 mediates osmotic stress-induced tight junction disruption in the intestinal epithelium.	MAPK8 MAPK9	6.48e-06	2	89	2	20595622
Pubmed	c-Jun NH2-terminal kinase is required for lineage-specific differentiation but not stem cell self-renewal.	MAPK8 MAPK9	6.48e-06	2	89	2	20065035
Pubmed	Inhibited neurogenesis in JNK1-deficient embryonic stem cells.	MAPK8 MAPK9	6.48e-06	2	89	2	16314504
Pubmed	c-Jun N-terminal kinase 2 suppresses pancreatic cancer growth and invasion and is opposed by c-Jun N-terminal kinase 1.	MAPK8 MAPK9	6.48e-06	2	89	2	33526844
Pubmed	JNK1 and 2 play a negative role in reprogramming to pluripotent stem cells by suppressing Klf4 activity.	MAPK8 MAPK9	6.48e-06	2	89	2	24211391
Pubmed	Characterization of NERF, a novel transcription factor related to the Ets factor ELF-1.	ELF1 ELF2	6.48e-06	2	89	2	8756667
Pubmed	Protective role of c-Jun N-terminal kinase-2 (JNK2) in ibuprofen-induced acute liver injury.	MAPK8 MAPK9	6.48e-06	2	89	2	30264435
Pubmed	Decreased expression of phosphorylated JNK in breast infiltrating ductal carcinoma is associated with a better overall survival.	MAPK8 MAPK9	6.48e-06	2	89	2	16381010
Pubmed	Protective role of c-Jun N-terminal kinase 2 in acetaminophen-induced liver injury.	MAPK8 MAPK9	6.48e-06	2	89	2	18586006
Pubmed	Cell lineage-specific interactions between Men1 and Rb in neuroendocrine neoplasia.	RB1 MEN1	6.48e-06	2	89	2	17893233
Pubmed	Pyruvate dehydrogenase E1 alpha subunit genes in the mouse: mapping and comparison with human homologs.	PDHA1 PDHA2	6.48e-06	2	89	2	2122529
Pubmed	Dynamic epigenetic regulation by menin during pancreatic islet tumor formation.	RB1 MEN1	6.48e-06	2	89	2	25537453
Pubmed	JNK/SAPK Signaling Is Essential for Efficient Reprogramming of Human Fibroblasts to Induced Pluripotent Stem Cells.	MAPK8 MAPK9	6.48e-06	2	89	2	26867034
Pubmed	Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein.	RB1 ELF1	6.48e-06	2	89	2	8493578
Pubmed	c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D.	MAPK8 MAPK9	6.48e-06	2	89	2	19339050
Pubmed	Isolation and characterisation of the mouse pyruvate dehydrogenase E1 alpha genes.	PDHA1 PDHA2	6.48e-06	2	89	2	1581363
Pubmed	Jun N-terminal kinase 1 regulates epithelial-to-mesenchymal transition induced by TGF-beta1.	MAPK8 MAPK9	6.48e-06	2	89	2	18334556
Pubmed	A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis.	MAPK8 MAPK9	6.48e-06	2	89	2	17202416
Pubmed	Deletion of JNK Enhances Senescence in Joint Tissues and Increases the Severity of Age-Related Osteoarthritis in Mice.	MAPK8 MAPK9	6.48e-06	2	89	2	32418287
Pubmed	The role of JNK in the development of hepatocellular carcinoma.	MAPK8 MAPK9	6.48e-06	2	89	2	21406557
Pubmed	JNK1/2 regulates ER-mitochondrial Ca2+ cross-talk during IL-1β-mediated cell death in RINm5F and human primary β-cells.	MAPK8 MAPK9	6.48e-06	2	89	2	23615449
Pubmed	Genetic deletion of JNK1 and JNK2 aggravates the DSS-induced colitis in mice.	MAPK8 MAPK9	6.48e-06	2	89	2	17365404
Pubmed	Pyruvate dehydrogenase complex: mRNA and protein expression patterns of E1α subunit genes in human spermatogenesis.	PDHA1 PDHA2	6.48e-06	2	89	2	22750801
Pubmed	Signal transduction by the JNK group of MAP kinases.	MAPK8 MAPK9	6.48e-06	2	89	2	11057897
Pubmed	Effect of Jun N-terminal kinase 1 and 2 on the replication of Penicillium marneffei in human macrophages.	MAPK8 MAPK9	6.48e-06	2	89	2	25792289
Pubmed	NDUFC2 deficiency exacerbates endothelial mesenchymal transformation during ischemia-reperfusion via NLRP3.	NDUFC2-KCTD14 NDUFC2	6.48e-06	2	89	2	37506315
Pubmed	Silencing Jnk1 and Jnk2 accelerates basal lipolysis and promotes fatty acid re-esterification in mouse adipocytes.	MAPK8 MAPK9	6.48e-06	2	89	2	18528680
Pubmed	VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system.	VRK1 VRK2	6.48e-06	2	89	2	36040810
Pubmed	Cyclin F Controls Cell-Cycle Transcriptional Outputs by Directing the Degradation of the Three Activator E2Fs.	CCNF CUL1 RB1	1.07e-05	17	89	3	31130363
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	RALGAPA1 IFRD1 TBC1D4 DST SUB1 TEX2 SPIRE1 DOCK6 REEP2 GOLGA4 SPATA13	1.27e-05	861	89	11	36931259
Pubmed	Oppositional regulation of Noxa by JNK1 and JNK2 during apoptosis induced by proteasomal inhibitors.	MAPK8 MAPK9	1.94e-05	3	89	2	23593480
Pubmed	JNK Isoforms Are Involved in the Control of Adult Hippocampal Neurogenesis in Mice, Both in Physiological Conditions and in an Experimental Model of Temporal Lobe Epilepsy.	MAPK8 MAPK9	1.94e-05	3	89	2	30685843
Pubmed	Overexpression or ablation of JNK in skeletal muscle has no effect on glycogen synthase activity.	MAPK8 MAPK9	1.94e-05	3	89	2	15013949
Pubmed	Arrestin-3 binds c-Jun N-terminal kinase 1 (JNK1) and JNK2 and facilitates the activation of these ubiquitous JNK isoforms in cells via scaffolding.	MAPK8 MAPK9	1.94e-05	3	89	2	24257757
Pubmed	MEK kinase 1 activity is required for definitive erythropoiesis in the mouse fetal liver.	MAPK8 MAPK9	1.94e-05	3	89	2	16081685
Pubmed	Inhibition of C-jun N-terminal kinase improves insulin sensitivity but worsens albuminuria in experimental diabetes.	MAPK8 MAPK9	1.94e-05	3	89	2	18971923
Pubmed	A central role for JNK in obesity and insulin resistance.	MAPK8 MAPK9	1.94e-05	3	89	2	12447443
Pubmed	Mcl-1 integrates the opposing actions of signaling pathways that mediate survival and apoptosis.	MAPK8 MAPK9	1.94e-05	3	89	2	19433446
Pubmed	JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis.	MAPK8 MAPK9	1.94e-05	3	89	2	21364637
Pubmed	LAF4 maps to mouse chromosome 1 and human chromosome 2q11.2-q12.	DST AFF3	1.94e-05	3	89	2	8662235
Interaction	H3-3A interactions	CCNF VRK1 ZMYND11 BRD2 RB1 PDHA1 SUB1 NAT10 ELF1 ELF2 INO80 CABIN1 COPS2 MEN1	4.90e-06	749	89	14	int:H3-3A
Interaction	TASOR interactions	CCNF BDP1 PPP2R2A TBC1D4 RB1 MEN1	9.27e-06	110	89	6	int:TASOR
Interaction	HDAC1 interactions	CCNF PPP2R2A ZMYND11 IFRD1 TBC1D4 DST ACACB RB1 TLN1 CCAR2 NUDCD1 MAPK8 MAPK9 CABIN1 GOLGA4 MEN1	2.48e-05	1108	89	16	int:HDAC1
GeneFamily	AF4/FMR2 family\|Super elongation complex	AFF2 AFF3	4.13e-05	4	48	2	1145
GeneFamily	AF4/FMR2 family\|Super elongation complex	AFF2 AFF3	2.46e-04	9	48	2	1280
GeneFamily	Mitogen-activated protein kinases	MAPK8 MAPK9	5.28e-04	13	48	2	651
GeneFamily	ETS transcription factor family	ELF1 ELF2	2.50e-03	28	48	2	534
GeneFamily	Sorting nexins\|PX-BAR domain containing	SNX32 SNX31	2.68e-03	29	48	2	754
GeneFamily	Ankyrin repeat domain containing	SLF1 ASAP3 TRPV3 ASB14	3.84e-03	242	48	4	403
Coexpression	GSE46606_DAY1_VS_DAY3_CD40L_IL2_IL5_STIMULATED_IRF4MID_BCELL_DN	VRK1 UPB1 BNIP2 MTMR1 ELF1 BCKDHA MAPK9	5.50e-06	200	89	7	M9842
Coexpression	LAKE_ADULT_KIDNEY_C20_COLLECTING_DUCT_INTERCALATED_CELLS_TYPE_A_CORTEX	RALGAPA1 BDP1 PDE1A NRXN3 TBC1D4 MAPK8	1.35e-05	152	89	6	M39239
ToppCell	Tracheal-10x5prime-Endothelial-Endothelia_vascular-VE_alveolar_capillary_Car4_aerocyte\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	CCNF FRY SLF1 CSF2RB CHST1 ZNF471	2.89e-06	198	89	6	c77421898cc84ae2e8cc335087198dd05f13bfa5
ToppCell	Control-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_3\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PDE1A IL17B CCDC80 CSMD2 NLRP4	2.40e-05	171	89	5	4ede831aed364cb5271f49a8b09bb6d0452f9b35
ToppCell	facs-Lung-24m-Endothelial-arterial_endothelial-pulmonary_artery_endothelial_cell-pulmonary_artery_endothelial_cell_l25\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	SLF1 ACACB TEX2 OLFM2 C16orf89	3.07e-05	180	89	5	baa5825e6ce23a98d9c21d024a4b0ab8ba353d0c
ToppCell	facs-Lung-24m-Endothelial-arterial_endothelial-pulmonary_artery_endothelial_cell\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	SLF1 ACACB TEX2 OLFM2 C16orf89	3.07e-05	180	89	5	2d608b9394d28d19cfc85c6ac94003d5177c8a92
ToppCell	facs-Lung-24m-Endothelial-arterial_endothelial\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	SLF1 ACACB TEX2 OLFM2 C16orf89	3.07e-05	180	89	5	0f9b27054358c4737eed06c8ea01987cccc3cb55
ToppCell	facs-Lung-nan-3m-Endothelial-Artery_endothelial_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DST CCDC80 OLFM2 ZNF471 C16orf89	3.32e-05	183	89	5	12e876d6205af8aad74265c668b5e95b9e7487f3
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	UPB1 NRXN3 AFF2 AFF3 SNX31	3.68e-05	187	89	5	ec4b694487cc446999c7b27b119950a4f252c4b3
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	UPB1 NRXN3 AFF2 AFF3 SNX31	3.68e-05	187	89	5	530e4e6d91b5c0d9aa4543caa2b734a1674c5788
ToppCell	renal_medulla_nuclei\|World / Celltypes from Cells and Nuclei per compartment and clinical group	PDE1A FRY TBC1D4 ACACB SIM2	3.87e-05	189	89	5	830d9cd0dd706bce22eb2416f07b2c31c870a05a
ToppCell	facs-Lung-3m-Endothelial-arterial_endothelial\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	DST CCDC80 OLFM2 REEP2 C16orf89	4.07e-05	191	89	5	6e6b2cb390cc5cd0356924a2c36fbe5b5bd5966c
ToppCell	facs-Lung-3m-Endothelial-arterial_endothelial-pulmonary_artery_endothelial_cell\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	DST CCDC80 OLFM2 REEP2 C16orf89	4.07e-05	191	89	5	482db995930346be69072ace2fd78fd453e97fb5
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	NRXN3 AFF2 AFF3 SNX31 ANO3	4.17e-05	192	89	5	24e2f15f5767a97eb3b389922bcfd7b13805e1ce
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	FRY NRXN3 IL17B AFF3 ANO3	4.17e-05	192	89	5	bfab13793e54de2550ee171397f7ece0625cdb4a
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	FRY NRXN3 IL17B AFF3 ANO3	4.17e-05	192	89	5	b54b0d5b88139905521c8d5d58332e89c08d589c
ToppCell	CV-Severe-6\|Severe / Virus stimulation, Condition and Cluster	RALGDS TLN1 SERINC3 ELF2 SPATA13	4.38e-05	194	89	5	d33be6ed1de907aeea0c2dce09796556b8efdd4e
ToppCell	CV-Severe-6\|CV / Virus stimulation, Condition and Cluster	RALGDS TLN1 SERINC3 EXOC2 SPATA13	4.49e-05	195	89	5	69095c6ce2a7e763afa543c10d5710e0c3dda769
ToppCell	COVID-19-kidney-TAL\|kidney / Disease (COVID-19 only), tissue and cell type	PDE1A TBC1D4 DST SPIRE1 SIM2	4.60e-05	196	89	5	04f5eb206ed3016a737609a3ebac0c1fcabb94ef
ToppCell	Tracheal-10x3prime_v2-Epithelial-Epi_airway_neuro-secretory\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	UPB1 KIF1A TRPV3 CHST1 REEP2	4.71e-05	197	89	5	ff4df77117165b6b25315e29b0722cc136eba607
ToppCell	LPS_anti-TNF-Endothelial-Endothelial-Activated_Alv_Cap\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	FRY SLF1 AFF3 SERINC3 MYZAP	5.06e-05	200	89	5	bcd1cc96197929d6011903803b6f4ccdcf52b4ce
ToppCell	Neuronal\|World / cells hierarchy compared to all cells using T-Statistic	BDP1 FRY NRXN3 SLF1 AFF3	5.06e-05	200	89	5	48d801219bc771d6c7e151dc88ca4c179988de85
ToppCell	LPS_anti-TNF-Endothelial-Endothelial-Alv_Gen_Intermediate\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	FRY SLF1 SERINC3 MYZAP DOCK6	5.06e-05	200	89	5	89a6da2bdedc6b1ad0675c8753bf2b763a99af6a
ToppCell	LPS_anti-TNF-Endothelial\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	DST SLF1 SERINC3 MYZAP DOCK6	5.06e-05	200	89	5	1d105eeda5a2c51f9a4654ffc79b7e2348ad593b
ToppCell	LPS_anti-TNF-Endothelial-Endothelial\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	DST SLF1 SERINC3 MYZAP DOCK6	5.06e-05	200	89	5	60d2cbf41f37f1b11eddb4c9d9246c9c1fc5a5af
ToppCell	LPS_only-Endothelial-Endothelial-Alv_Cap\|LPS_only / Treatment groups by lineage, cell group, cell type	FRY SLF1 AFF3 SERINC3 MYZAP	5.06e-05	200	89	5	432384faeade8e609154fab3d96c955a8ec868dd
ToppCell	Striatum-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Adora2a\|Striatum / BrainAtlas - Mouse McCarroll V32	DRD2 UPB1 SNX31 ANO3	6.79e-05	109	89	4	e8e0f2c5f8c9e45f2b4d173569c94275eedfe432
Drug	pramipexole	DRD2 MAPK8 MAPK9	1.15e-06	6	89	3	ctd:C061333
Drug	Polysaccharides	RB1 PDHA1 FBP2 MAPK8 MAPK9	6.99e-06	68	89	5	ctd:D011134
Disease	pyruvate decarboxylase deficiency (implicated_via_orthology)	PDHA1 PDHA2	2.69e-05	3	89	2	DOID:3649 (implicated_via_orthology)
Disease	migraine with aura (is_implicated_in)	DRD2 TRPV3	1.34e-04	6	89	2	DOID:10024 (is_implicated_in)
Disease	alcohol use disorder measurement, longitudinal alcohol consumption measurement	VRK2 DRD2 ANO3	1.91e-04	37	89	3	EFO_0007645, EFO_0009458
Disease	Pituitary Neoplasms	DRD2 MEN1	2.49e-04	8	89	2	C0032019
Disease	type 2 diabetes mellitus (implicated_via_orthology)	AFF2 AFF3 MAPK8 MAPK9	2.93e-04	105	89	4	DOID:9352 (implicated_via_orthology)
Disease	Pituitary Adenoma	DRD2 MEN1	3.19e-04	9	89	2	C0032000
Disease	S-7-hydroxywarfarin measurement	AFF3 MYZAP CSMD2 HERC4	3.50e-04	110	89	4	EFO_0803329
Disease	Intellectual Disability	RALGAPA1 PRR12 RALGDS FRY VRK1 ZMYND11 AFF3	4.14e-04	447	89	7	C3714756
Disease	Trigeminal Neuralgia	MAPK8 MAPK9	5.82e-04	12	89	2	C0040997
Disease	Secondary Trigeminal Neuralgia	MAPK8 MAPK9	5.82e-04	12	89	2	C0393787
Disease	Trigeminal Neuralgia, Idiopathic	MAPK8 MAPK9	5.82e-04	12	89	2	C0393786
Disease	systolic blood pressure, cigarettes per day measurement	FRY NRXN3	6.87e-04	13	89	2	EFO_0006335, EFO_0006525
Disease	renal agenesis, unilateral	GLYATL1 TBC1D4 COPS2	8.41e-04	61	89	3	MONDO_0019636
Disease	amyotrophic lateral sclerosis, age at onset	IFRD1 NRXN3	9.21e-04	15	89	2	EFO_0004847, MONDO_0004976
Disease	susceptibility to chronic sinus infection measurement	PDHA1 AFF3 NLRP4	1.15e-03	68	89	3	EFO_0008419
Disease	caudal middle frontal gyrus volume measurement	FRY FBP2	1.33e-03	18	89	2	EFO_0010290
Disease	Adrenocortical carcinoma	RB1 MEN1	1.33e-03	18	89	2	C0206686
Disease	disease of metabolism (implicated_via_orthology)	PDHA1 PDHA2	1.82e-03	21	89	2	DOID:0014667 (implicated_via_orthology)
Disease	Liver Failure, Acute	SERPINC1 MAPK8	2.38e-03	24	89	2	C0162557

Protein segments in the cluster

Peptide	Gene	Start	Entry
EMLQRDFGYRVYKML	CCAR2	546	Q8N163
MYSETVELIRYAMRL	AFF3	1031	P51826
YRQFVKRIGYMIRMT	EPG5	636	Q9HCE0
RSKMTMRDFIYYLPD	BDP1	181	A6H8Y1
ESDMGTRRDYIMAKY	ASAP3	521	Q8TDY4
MMDLNRRAEAIGYAY	C16orf89	231	Q6UX73
KPDMNYETMGRALRY	ELF1	256	P32519
YIEIRNGPYETSRMM	CSMD2	2021	Q7Z408
PEMMNRYKQLLTYIR	COPS2	86	P61201
SGRYMMTRDYLSVKI	PPP2R2A	296	P63151
RRILGYSMQEMYDVV	COQ10B	81	Q9H8M1
MYSETVELLRYAMRL	AFF2	1126	P51816
LKDEVMLRMLLNYGY	ASB14	431	A6NK59
SRFKVMDDQYRTLMR	DNHD1	1286	Q96M86
ASMMYQEGKFRYRRV	SERPINC1	281	P01008
YSDLMESVTYMRLKG	CC2D2B	686	Q6DHV5
EGYYRLMMSLLKDDV	CCDC80	161	Q76M96
IRREKYLVQEMMYEA	ANO3	946	Q9BYT9
LAMLMLDSYYRTIKG	MTMR1	451	Q13613
YKLGVRLYYRVMESM	RB1	446	P06400
RLYYRVMESMLKSEE	RB1	451	P06400
TYRDLQYVRGMETLM	OLFM2	86	O95897
MTRMIDLLEEYMVYR	INO80	1126	Q9ULG1
YYIDTLGRIMNLTVM	NUDCD1	76	Q96RS6
LYRMKSGNRVATFMI	P4HA3	451	Q7Z4N8
LYLKGSYMRCDRKME	MEN1	226	O00255
KIEESVRYMVMRYGS	ACACB	1606	O00763
ERMSYLLYQMLCGIK	MAPK9	126	P45984
RYSESMKILREMYER	LIN37	231	Q96GY3
SRMKPYARMEEYERN	IL17B	51	Q9UHF5
EYLRKVLFEYMMGRE	GOLGA4	2176	Q13439
TVKDYELQTMTYRAM	DST	1361	Q03001
MLTLTRYVMEKGRQA	FBP2	11	O00757
MNYYDMRTDRNKGIP	EXOC2	111	Q96KP1
ERMSYLLYQMLCGIK	MAPK8	126	P45983
VERMYRKTYHMVGLA	PDE1A	131	P54750
IMRELLDPKYGMFRY	HERC4	761	Q5GLZ8
SCEVGMAYSMEKYRR	GLYATL1	226	Q969I3
MAYSMEKYRRTGNMA	GLYATL1	231	Q969I3
REASILSYDGSMYMK	NRXN3	681	Q9Y4C0
MALRKYPVRYEESMN	DNAH12	2836	Q6ZR08
LYAVRDREMFGYMKL	NDUFC2	81	O95298
MKVMRERTGYTKTYQ	NLRP4	86	Q96MN2
LYREVMRMNYETVLS	POGK	71	Q9P215
DLKRLEMYSRNMVDY	NAT10	821	Q9H0A0
GDSYSLRWETMKMRY	CSF2RB	351	P32927
YDLGRVERIMSETYM	CABIN1	1876	Q9Y6J0
EMLIDLMYRIARGYQ	DOCK6	1576	Q96HP0
TDNTYKYEDLVRMMG	CCNF	381	P41002
FKMTGRYEMYARELA	UPB1	356	Q9UBR1
VYTRQSMAKSRYMEL	CUL1	31	Q13616
YMIVYLNGATTRRKM	BNIP2	206	Q12982
KPDMNYETMGRALRY	ELF2	256	Q15723
ASKMLYEFILERRMT	IFRD1	111	O00458
MLDTAMKDYLYGRLI	RALGDS	576	Q12967
LVLGMSMYYRTILLD	MARVELD2	271	Q8N4S9
VAMPMLYNTRYSSKR	DRD2	136	P14416
EAKMIGMSLYYSQVR	FRY	546	Q5TBA9
QLYRMMDKGVLSYWR	PKD1L1	2541	Q8TDX9
REKIYMTLSAYIEME	KIF1A	1261	Q12756
YKSMTLLNTMDRILY	BCKDHA	106	P12694
RAEGLKYYRMMLTVR	PDHA2	56	P29803
MTYSVKEMEYLTRAI	NXPE4	406	Q6UWF7
TKYKYTEIRLDGMRM	PKDREJ	1651	Q9NTG1
SGYLKIRQYMLDMSL	SIM2	186	Q14190
DNMFQIGKMRYVSVR	SUB1	61	P53999
LKTRAMREMYRSYVE	PRR12	1841	Q9ULL5
PKYYLAMTTAMADER	SNX31	61	Q8N9S9
MDMGTIKRRLENNYY	BRD2	121	P25440
SVMSEMAPRDLKAYY	CIB3	96	Q96Q77
KYMLVRYEDLARNPM	CHST1	296	O43916
LRRDMLYYKGRLDMD	SPATA13	491	Q96N96
LMRYRMYETVDEGLK	POGLUT3	101	Q7Z4H8
AREMERLEMYYARLG	TMEM74B	156	Q9NUR3
YITQARDKSYETMMR	REEP2	106	Q9BRK0
DMCKRILNIYRYMVV	RALGAPA1	556	Q6GYQ0
LTREDGLKYYRMMQT	PDHA1	56	P08559
YMLRNGDTMEYRKKQ	TLN1	71	Q9Y490
YEMLMDDIRCKRYTL	SPIRE1	306	Q08AE8
VVSYIMQRKEMETYL	SERINC3	51	Q13530
FLEMKGALRETMYRT	SLF1	231	Q9BQI6
YDLGFRKQYRPDMMS	TBC1D4	1036	O60343
YRFMIMDRFGSDLQK	VRK1	126	Q99986
LYAVRDREMFGYMKL	NDUFC2-KCTD14	81	E9PQ53
KRLYRSMMLENYQSL	ZNF471	36	Q9BX82
QEMGTYLRFIVSRMK	ZMYND11	156	Q15326
FVKRMYDMILLRSGN	TRPV3	316	Q8NET8
GSVRQKMLLDYSVYM	TEX2	766	Q8IWB9
DLKLSDMLRYYMRDS	SNX32	286	Q86XE0
YRFMVMERLGIDLQK	VRK2	116	Q86Y07
VYLERMGMYKIILNQ	LEG1	56	Q6P5S2
KRMYGDYDEMRQKIR	MYZAP	116	P0CAP1